New approaches to using antiretroviral therapy for the management of HIV infection

Annals of Pharmacotherapy

Volumn 31, Issue 2, 1997, Pages 228-236

  Doran, Cynthia M ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG SURVEILLANCE PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VERTICAL TRANSMISSION;

EID: 0031033624     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100215     Document Type: Review

References (51)

1. El-Sadr W, Oleske JM, Agins BD, Bauman KA, Brosgart CL, Brown GM, et al. Evaluation and management of early HIV infection. Clinical Practice Guideline No. 7. AHCPR Publication No. 94-0572. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, January 1994.
2. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-57.
3. Saag MS, Holodniy M, Kuritzkes D, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice: recommendations of an International AIDS Society - USA expert panel. Nat Med 1996; 82:625-9.
4. Kaplan JE, Masur H, Holmes KK, eds. Prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(suppl 1):S1-141.
5. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
6. Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
7. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
8. Ho DD. Time to hit HIV, early and hard (editorial). N Engl J Med 1995; 333:450-1. 9.
9. Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995;123:641-8.
10. Wauen LK, Nickens DJ, Chuang-Stein CJ, Crampton DJ, Mickelson PM, Carberry PA, et al. HIV-1 RNA viral burden at baseline or its reduction following antiretroviral therapy is highly correlated with reduced HIV-1 disease progression. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28February 1, 1996.
11. Recommendations to the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43:1-20.
12. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331: 1173-80.
13. Peckham C, Gibb D. Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med 1995;333:298-302.
14. Pinching AJ. Managing HIV disease after Delta. BMJ 1996;312:521-2.
15. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-25.
16. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333:1662-9.
17. Staszewski S, Loveday C, Picazo JJ, Dellamonica P, Skinhøj P, Johnson MA, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:111-7.
18. 3 (abstract). Presented at the Second National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29February 2, 1995.
19. Collier AC, Coombs RW, Schoenfeld DA, Bassett RV, Timpone J, Baruch A. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
20. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119: 786-93.
21. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1994;122:24-32.
22. Yarchoan R, Lietzau JA, Nguyen BY, Vrawley OW, Pluda JM, Saville W, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994;169:9-17.
23. Montaner J, Cooper D, Katlama C, Stoffels P, Hill A, Goh L, et al. CAESAR: Confirmation of the clinical benefit of 3TC (Epivir) in HIV-1 disease: preliminary results (abstract). Presented at the Thirty-sixth Interscience Conference of Antimicrobials Agents and Chemotherapy, New Orleans, LA, September 15-18, 1996.
24. Ioannidis JPA, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. A model of the predictive value of viral load measurements in asymptomatic untreated HIV-1 infection. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
25. Follansbee SE, Mitchell TF, Charlebois E, Child C, Pell P, Chernoff D, et al. The impact of initiation or change in antiretroviral therapy on HIV plasma RNA load as measured by bDNA assay. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
26. Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, Boyer PJ, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
27. Spooner KM, Lane HC, Masur H, Antiretroviral therapy: reference guide to major clinical trials in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;20:1145-51.
28. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
29. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-22.
30. Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
31. Mellors JW, Rinaldo DP Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
32. Lu W, Grassi F, Tourani JM, Erne D, Israel-Biet D, Andrieu JM. High concentration of peripheral blood mononuclear cells harboring infectious virus correlates with rapid progression of human immunodeficiency virus type 1-related diseases. J Infect Dis 1993;168:1165-8.
33. Greene WC. Predicting progression to AIDS (editorial). Ann Intern Med 1995;123:726-7.
34. Niu MT, Stein DS, Schnittman SM, Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993; 168:1490-501.
35. Cooper DA. Early antiretroviral therapy. AIDS 1994;8(suppl 3):S9-14.
36. Schooley RT. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs, AIDS 1995;9(suppl 2):S15-9.
37. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng T, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-intected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995;333:401-7.
38. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994;330:738-43.
39. loannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: a meta-analysis. Ann Intern Med 1995;122:856-66.
40. Todd J, Yeghiazarian T, Hoo B, Detmer J, Kolberg J, White R, et al. Quantitäten of human immunodeficiency virus plasma RNA by branched DNA and reverse transcription coupled polymerase chain reaction assay methods: a critical evaluation of accuracy and reproducibility. Serodiagnos Immunother Infect Dis 1994;6:233-9.
41. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
42. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528- 33.
43. Cameron B, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28- February 1, 1996.
44. Tsoukas CM, Bernard NF. Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev 1994;7:14-28.
45. Massari F, Conant M, Mellors J, Steigbigel R, Mildvan D, Greenberg R, et al. A Phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (ddI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
46. Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28-February 1, 1996.
47. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-636 (indinavir). AIDS 1996;10:485-92.
48. Pachl C, Yeghiazarian T, Hoo B, Besemer D, Fong SJ, Stempien M, et al. Comparison of the branched DNA (bDNA) signal amplification assay with immune complex dissociated (ICD) p24 antigen assay for the detection of HIV in plasma. Presented at the Pan-American Group for Rapid Viral Diagnosis Clinical Virology Symposium, Clearwater, FL, April 25-28, 1993.
49. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection, N Engl J Med 1992;327:581- 7.
50. Dolin R, Amato DA, Fischl MA, Liou S, Smaldone L, Pettinelli C. Efficacy of didanosine (ddI) versus zidovudine (ZDV) in patients with no or ≤16 weeks of prior ZDV therapy (abstract). In: Program and abstracts of the 9th International Conference on AIDS (Berlin). Berlin: Institute for Clinical and Experimental Virology of the Free University of Berlin, 1993:122.
51. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH, Reichman RC, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272:437-42.